Liquidia Corporation (LQDA) vs Regencell Bioscience Holdings Limited (RGC)

Liquidia Corporation and Regencell Bioscience Holdings Limited are both Drug Manufacturers Specialty & Generic companies. Liquidia Corporation is the larger, with a market value of $4.0B against $2.6B — 1.5× the size. Regencell Bioscience Holdings Limited has negative trailing earnings, so its P/E is not meaningful; Liquidia Corporation trades at 28.5×. Liquidia Corporation has the higher net margin (30.7% vs 0.00%) and the higher return on invested capital (121.1% vs 0.00%). Across the 12 metrics below, Liquidia Corporation leads on 9 and Regencell Bioscience Holdings Limited on 3.

Valuation

Metric LQDA RGC Drug Manufacturers Specialty & Generic median
P/E 28.47 n/m 20.55
P/S 8.81 — 2.08
P/B 20.36 n/m 1.79
Price to free cash flow 26.36 n/m 16.29
EV/EBITDA 22.70 1.13 12.22
EV/Sales 8.57 n/m 2.87
Earnings yield 3.51% (19.96%) (15.94%)
Free cash flow yield 3.79% 0.00% 0.00%

Profitability

Metric LQDA RGC Drug Manufacturers Specialty & Generic median
Gross margin 92.54% — 53.51%
Operating margin 37.39% — 0.00%
Net margin 30.74% 0.00% (2.45%)
Free cash flow margin 33.42% 0.00% 0.00%
Return on equity 131.82% 0.00% (0.80%)
Return on assets 35.57% 0.00% (1.67%)
Return on invested capital 121.05% 0.00% 0.00%

Growth

Metric LQDA RGC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 2,233.65% — 5.22%
EPS growth (last fiscal year) 51.81% (177.78%) 42.91%
Revenue growth, 5-year CAGR 192.49% — 7.24%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LQDA RGC Drug Manufacturers Specialty & Generic median
Debt to equity 0.90 0.00 0.04
Current ratio 2.31 10.77 2.41
Net debt to EBITDA (0.01) 1.22 1.01

Dividend

Metric LQDA RGC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric LQDA RGC Drug Manufacturers Specialty & Generic median
Market cap 3.98b 2.61b 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack